Trials / Completed
CompletedNCT00345956
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)
A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 375 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 10 Weeks
- Healthy volunteers
- Accepted
Summary
To provide specific data on immunogenicity of GSK Biologicals' HRV liquid vaccine, when co-administered with the routine Expanded Program of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety of the HRV liquid vaccine relative to the placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human rotavirus liquid vaccine |
Timeline
- Start date
- 2006-09-01
- Completion
- 2007-03-01
- First posted
- 2006-06-29
- Last updated
- 2016-10-28
Locations
2 sites across 1 country: Vietnam
Source: ClinicalTrials.gov record NCT00345956. Inclusion in this directory is not an endorsement.